<DOC>
	<DOC>NCT00158795</DOC>
	<brief_summary>To assess safety and reactogenicity of GSK Biologicals' Haemophilus influenza type b vaccine co-administered with or without Chinese DTPw vaccine administered alone in healthy infants (3, 4 and 5 months of age)</brief_summary>
	<brief_title>Assess Safety &amp; Reactogenicity of GSK Biologicals' Hib Vaccine Co-administered With or Without Chinese DTPw Vaccine</brief_title>
	<detailed_description>All subjects will be randomized into two groups. One group will receive DTPw vaccine co-administered with Hib and another group will receive DTPw vaccine alone. A specific follow-up of solicited local and general symptoms after each vaccination. A specific follow-up of unsolicited symptoms after each vaccination. Recording of serious adverse events reported during the study period.</detailed_description>
	<mesh_term>Vaccines</mesh_term>
	<criteria>A male or female infant between, and including, 11 and 17 weeks of age at the time of the first vaccination. Planned administration of a vaccine not foreseen by the study protocol during the period starting 30 days before the administration of the first vaccine dose and ending 30 days after the last dose. Chronic administration of immunosuppressants or other immunemodifying drugs from birth until administration of first dose of study vaccine. Use of any investigational or nonregistered product (drug or vaccine) within 30 days preceding the first dose of study vaccine, or planned use during the study period.</criteria>
	<gender>All</gender>
	<minimum_age>3 Months</minimum_age>
	<maximum_age>4 Months</maximum_age>
	<verification_date>September 2011</verification_date>
</DOC>